Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Ligand Pharmaceuticals (United States) | Researchclopedia

Back to institutions

Ligand Pharmaceuticals (United States)

San Diego, Californiacompany

685

Works

151,314

Citations

160

h-index

Top Research Topics

Estrogen and related hormone effects Retinoids in leukemia and cellular processes Antioxidant Activity and Oxidative Stress

Top Researchers

Ronald M. Evans Salk Institute for Biological Studies

923 works188,887 citationsh-index: 211

Recent Research

Single-Pass Discrete Diffusion Predicts High-Affinity Peptide Binders at >1,000 Sequences per Second across 150 Receptor Targets

20260 citations

Peroxisome Proliferator-Activated Receptors

Cytokine Signaling Pathways and Interactions

Hormonal and reproductive studies

Receptor Mechanisms and Signaling

Bioactive Compounds and Antitumor Agents

Monoclonal and Polyclonal Antibodies Research

Hormonal Regulation and Hypertension

Adipose Tissue and Metabolism

Reproductive System and Pregnancy

David A. Wheeler St. Jude Children's Research Hospital

601 works130,466 citationsh-index: 147

Johan Auwerx Hôpital américain de paris

911 works125,354 citationsh-index: 183

Bart Staels Inserm

1,191 works109,632 citationsh-index: 167

Ramaswamy Govindan Barnes-Jewish Hospital

1,205 works96,744 citationsh-index: 127

Frederick W. Alt Boston Children's Hospital

636 works95,900 citationsh-index: 172

Bento: Benchmarking Classical and AI Docking on Drug Design–Relevant Data

Marina A. Pak,Daria Frolova,et al.

20250 citations

KRASAVA—An Expert System for Virtual Screening of KRAS G12D Inhibitors

Oleg V. Tinkov,Pavel E. Gurevich,et al.

20250 citations

Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

Melissa R. Junttila,Claire E. Repellin,et al.

20251 citations

PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia

Britten Gordon,Elizabeth M. Muhowski,et al.

20251 citations

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Ibrahim Aldoss,Carl Shultz,et al.

20252 citations